Norbert Bischofberger ices a PhIII AML drug — for the second time in his career
Norbert Bischofberger went back to his old colleagues at Gilead to pluck an AML drug off its back shelves and put it into the late-stage pipeline at Kronos. And last spring he even worked out a shorter Phase III path at the FDA for the SYK inhibitor using a unique primary endpoint.
But it wasn’t enough.
After the market closed Tuesday, Bischofberger pulled the plug on the Phase III, beleaguered by a host of issues “including the operational challenges the company faced in enrolling a genetically defined subset of patients in a front-line setting, the residual and ongoing impacts of the COVID-19 pandemic, and the inability to activate planned clinical trial sites in Russia and Ukraine.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.